Abbott Laboratories (ABT)

Abbott Laboratories, adjusted current assets

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Current assets
	Adjustments
	Add: Allowances for doubtful accounts and product returns
	Less: Deferred income taxes1
	After Adjustment
	Adjusted current assets

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).

Abbott Laboratories, adjusted total assets

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Total assets
	Adjustments
	Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
	Add: Allowances for doubtful accounts and product returns
	Less: Deferred income taxes2
	After Adjustment
	Adjusted total assets

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).

Abbott Laboratories, adjusted total liabilities

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Total liabilities
	Adjustments
	Add: Operating lease liability (before adoption of FASB Topic 842)1
	Less: Deferred income taxes2
	Less: Restructuring Plans, accrued balance
	After Adjustment
	Adjusted total liabilities

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).

Abbott Laboratories, adjusted total Abbott shareholders’ investment

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Total Abbott shareholders’ investment
	Adjustments
	Less: Net deferred tax assets (liabilities)1
	Add: Allowances for doubtful accounts and product returns
	Add: Restructuring Plans, accrued balance
	Add: Noncontrolling interests in subsidiaries
	After Adjustment
	Adjusted total shareholders’ investment

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).

Abbott Laboratories, adjusted capitalization table

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Short-term borrowings
	Current portion of long-term debt
	Long-term debt, excluding current portion
	Total reported debt
	Total Abbott shareholders’ investment
	Total reported capital
	Adjustments to Debt
	Add: Operating lease liability (before adoption of FASB Topic 842)1
	Adjusted total debt
	Adjustments to Equity
	Less: Net deferred tax assets (liabilities)2
	Add: Allowances for doubtful accounts and product returns
	Add: Restructuring Plans, accrued balance
	Add: Noncontrolling interests in subsidiaries
	Adjusted total shareholders’ investment
	After Adjustment
	Adjusted total capital

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).

Abbott Laboratories, adjusted net earnings

US$ in millions

	12 months ended	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Net earnings
	Adjustments
	Add: Deferred income tax expense (benefit)1
	Add: Increase (decrease) in allowances for doubtful accounts and product returns
	Add: Increase (decrease) in restructuring Plans, accrued balance
	Less: Net earnings from discontinued operations, net of taxes
	Add: Other comprehensive income (loss)
	After Adjustment
	Adjusted net earnings

Based on: 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-27).